New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Recent Patents on CNS Drug Discovery

• Publication date

  2013-07-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/1574889811308020003PMID 23597304PMCID PMC5831731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cholinesterase inhibitors for Alzheimer ' s disease ( Review )

  2022influential reference
• Butyrylcholinesterase and the cholinergic system.

  2013cited by this paper
• Editorial: neuroprotection and neuroregeneration in ischemic stroke: emerging treatment strategies and potential molecular targets.

  2013cited by this paper
• Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure.

  2013cited by this paper
• M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells

  2013influential reference
• Butyrylcholinesterase Is Associated With &bgr;-Amyloid Plaques in the Transgenic APPSWE/PSEN1dE9 Mouse Model of Alzheimer Disease

  2012cited by this paper
• The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5′Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression

  2012cited by this paper
• The impact of acetylcholinesterase inhibitors on the extracellular acetylcholine concentrations in the adult rat brain: A meta‐analysis

  2012cited by this paper
• Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

  2012cited by this paper
• Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

  2012cited by this paper
• Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor.

  2012cited by this paper
• M2 muscarinic receptors inhibit cell proliferation in human glioblastoma cell lines.

  2012cited by this paper
• Functions of Aβ, sAPPα and sAPPβ : similarities and differences

  2012cited by this paper
• Synaptic dysfunction in Alzheimer's disease.

  2012cited by this paper
• Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.

  2012cited by this paper
• Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients

  2012cited by this paper
• Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer, Inhibits Amyloid-β-Mediated Alzheimer's Disease-Associated Pathogenesis In Vitro and In Vivo

  2012cited by this paper
• Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation

  2012cited by this paper
• Phenserine Efficacy in Alzheimer's Disease

  2011cited by this paper
• Novel anti-Alzheimer’s dimer bis(7)-Cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets

  2011cited by this paper
• Donepezil in a Narrow Concentration Range Augments Control and Impaired by Beta-Amyloid Peptide Hippocampal LTP in NMDAR-Independent Manner

  2011cited by this paper
• Binding of huperzine A and galanthamine to acetylcholinesterase, based on ONIOM method.

  2011cited by this paper
• Alzheimer's disease and age-related memory decline (preclinical).

  2011cited by this paper
• Cholinesterase Inhibitors Improve Both Memory and Complex Learning in Aged Beagle Dogs

  2011cited by this paper
• Role of Acetylcholinesterase on the Structure and Function of Cholinergic Synapses: Insights Gained from Studies on Knockout Mice

  2011cited by this paper
• Stimulating Nicotinic Receptors Trigger Multiple Pathways Attenuating Cytotoxicity in Models of Alzheimer's and Parkinson's Diseases

  2011cited by this paper
• Contributions of selective knockout studies to understanding cholinesterase disposition and function.

  2010cited by this paper
• Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues.

  2010cited by this paper
• Early Stages of Pathogenesis in Memory Impairment during Normal Senescence and Alzheimer's Disease

  2010cited by this paper
• Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease

  2010cited by this paper
• Structure, activities and biomedical applications of human butyrylcholinesterase.

  2009influential reference
• Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.

  2009cited by this paper
• Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice.

  2009cited by this paper
• Cholinesterase inhibitors and beyond.

  2009cited by this paper
• The neurology of the immune system: neural reflexes regulate immunity.

  2009cited by this paper
• Chapter 15: Novel pharmacological approaches to Schwann cells as neuroprotective agents for peripheral nerve regeneration.

  2009cited by this paper
• Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase.

  2008cited by this paper
• Acetylcholinesterase: how is structure related to function?

  2008influential reference
• Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy.

  2008cited by this paper
• Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

  2008cited by this paper
• Acetylcholine inhibits cell cycle progression in rat Schwann cells by activation of the M2 receptor subtype.

  2007cited by this paper
• M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion.

  2007influential reference
• N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.

  2007influential reference
• Butyrylcholinesterase activity in the rat forebrain and upper brainstem: postnatal development and adult distribution.

  2007cited by this paper
• Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine

  2007cited by this paper
• The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

  2007cited by this paper
• Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

  2007cited by this paper
• Acetylcholine and regulation of gene expression in developing systems

  2007cited by this paper
• Phenserine

  2007cited by this paper
• Excessive hippocampal acetylcholine levels in acetylcholinesterase‐deficient mice are moderated by butyrylcholinesterase activity

  2007cited by this paper
• Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine

  2006cited by this paper
• Preclinical Evidence of Neuroprotection by Cholinesterase Inhibitors

  2006cited by this paper
• Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

  2006cited by this paper
• The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

  2006influential reference
• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• Control by cholinergic mechanisms.

  2006cited by this paper
• Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through Src-like tyrosine kinases and PI3K/Akt pathways.

  2006cited by this paper
• Rat Schwann cells express M1–M4 muscarinic receptor subtypes

  2006cited by this paper
• Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance.

  2006cited by this paper
• Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.

  2006cited by this paper
• A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis.

  2006cited by this paper
• The Clinical Pharmacokinetics of Darifenacin

  2006cited by this paper
• Migrastatin Acts as a Muscarinic Acetylcholine Receptor Antagonist

  2006cited by this paper
• Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.

  2006cited by this paper
• Muscarinic cholinergic receptors in the human melanoma cell line SK‐Mel 28: modulation of chemotaxis

  2005cited by this paper
• Journal of Neuroinflammation BioMed Central

  2005cited by this paper
• Selective Targeting of Muscarinic Receptors: Novel Therapeutic Approaches for Psychotic Disorders

  2005cited by this paper
• Cholinesterases: roles in the brain during health and disease.

  2005cited by this paper
• Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives.

  2005cited by this paper
• An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

  2005cited by this paper
• Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis.

  2005cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

  2005cited by this paper
• Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells

  2005cited by this paper
• Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years

  2005cited by this paper
• Targeting acetylcholinesterase and butyrylcholinesterase in dementia.

  2005cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

  2005influential reference
• Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects.

  2005cited by this paper
• Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron

  2004cited by this paper
• Galantamine for Alzheimer's disease.

  2004cited by this paper
• Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.

  2004cited by this paper
• Signaling cascades implicated in muscarinic regulation of proliferation of neural stem and progenitor cells.

  2004cited by this paper
• Identification of a structural site on acetylcholinesterase that promotes neurite outgrowth and binds laminin-1 and collagen IV.

  2004cited by this paper
• Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells.

  2004cited by this paper
• Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function.

  2004cited by this paper
• Muscarinic acetylcholine receptors involved in the regulation of neural stem cell proliferation and differentiation in vitro

  2004cited by this paper
• Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications.

  2004cited by this paper
• Tiotropium Bromide

  2004influential reference
• The airway cholinergic system: physiology and pharmacology.

  2004cited by this paper
• Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: a review.

  2003cited by this paper
• Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma.

  2003cited by this paper
• Neurobiology of butyrylcholinesterase

  2003cited by this paper
• The non-neuronal cholinergic system in humans: expression, function and pathophysiology.

  2003cited by this paper
• Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease

  2003cited by this paper
• Regulation of muscarinic acetylcholine receptor signaling.

  2003cited by this paper
• Sjogren’s syndrome: evolving therapies

  2003cited by this paper
• Galantamine for Alzheimer's disease.

  2002cited by this paper
• Muscarinic M2 Receptors on Peripheral Nerve Endings: A Molecular Target of Antinociception

  2002cited by this paper
• Complex regulation of acetylcholinesterase gene expression in human brain tumors

  2002cited by this paper
• Butyrylcholinesterase: An Important New Target in Alzheimer's Disease Therapy

  2002cited by this paper
• Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients.

  2002cited by this paper

• Characterization of a Novel Family of Contilisant + Belinostat Multitarget Small Molecules in Glioblastoma

  2025cites this paper
• Treatment Of Schizophrenia With Cobenfy (KarXT): A Literature Review

  2025cites this paper
• Muscarinic acetylcholine receptor activated effectors in principal neurons of the rat basolateral amygdala

  2025cites this paper
• The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons.

  2024cites this paper
• Deepening insights into cholinergic agents for intraocular pressure reduction: systems genetics, molecular modeling, and in vivo perspectives

  2024cites this paper
• Cholinergic Mechanisms in Gastrointestinal Neoplasia

  2024cites this paper
• 8-[(4-benzylpiperazin-1-yl)methyl]-3-(2-chlorophenyl)-7-hydroxy-chromen-4-one is an activator of contractile activity of intestinal smooth muscles with reversible M2 cholinomimetic properties

  2023cites this paper
• Profiling Novel Quinuclidine-Based Derivatives as Potential Anticholinesterase Drugs: Enzyme Inhibition and Effects on Cell Viability

  2023influential citation
• Toxin-like Peptides from the Bacterial Cultures Derived from Gut Microbiome Infected by SARS-CoV-2—New Data for a Possible Role in the Long COVID Pattern

  2022cites this paper
• Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease

  2022cites this paper
• Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

  2021influential citation
• Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm

  2021cites this paper
• Muscarinic Acetylcholine Receptors in the Retina—Therapeutic Implications

  2021cites this paper
• Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug

  2021cites this paper
• Cholinergic Modulation of the Immune System in Neuroinflammatory Diseases

  2021cites this paper
• Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases

  2021cites this paper
• Evaluation of neuroprotective activity of isolated fraction from Biophytum sensitivum on #945;-(hydroxymethyl) Benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo non-7-yl ester induced dementia in rats

  2020cites this paper
• Pharmacology of Acetylcholine and Cholinergic Receptors

  2020cites this paper
• Pharmacologie du système cholinergique

  2019cites this paper
• Alkyl derivatives of 1,3,5-triazine as histamine H4 receptor ligands.

  2019cites this paper
• Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory

  2019cites this paper
• Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus

  2018cites this paper
• Muscarinic M1 and M2 receptors, fasting and seizure development in animals

  2018cites this paper
• (R)-α-Lipoyl-Gly-l-Pro-l-Glu dimethyl ester as dual acting agent for the treatment of Alzheimer's disease.

  2017cites this paper
• Regulation of Human 69-kDa Choline Acetyltransferase Protein Stability and Function by Molecular Chaperones and the Ubiquitin-Proteasome System

  2017cites this paper
• M2 muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells

  2017cites this paper
• Cholinergic mechanisms of headaches

  2017cites this paper
• Cholinergic activation affects the acute and chronic antinociceptive effects of morphine.

  2017cites this paper
• Current and Future Issues in the Development of Spinal Agents for the Management of Pain

  2017cites this paper
• Prediction of consensus binding mode geometries for related chemical series of positive allosteric modulators of adenosine and muscarinic acetylcholine receptors

  2017cites this paper
• Chapter 13 – Cholinomimetics

  2016cites this paper
• Titolo della ricerca : Cholinergic control of myelination in Schwann cells and in Schwann cell-like induced from mesenchymal stem cells

  2016cites this paper
• M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding.

  2015cites this paper
• Cytotoxic and genotoxic effects mediated by M2 muscarinic receptor activation in human glioblastoma cells.

  2015cites this paper
• Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?

  2014cites this paper
• M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Identification and Modulation of Esterases Involved in the Metabolism of Heroin

  2014cites this paper
• Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.

  2014cites this paper
• Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?

  2014cites this paper
• Sequence-structure based phylogeny of GPCR Class A Rhodopsin receptors.

  2014cites this paper
• Regulation of expression and cellular release of acetylcholinesterase

  2013cites this paper